Treatment of Synchronous Mantle Cell Lymphoma and Small Lymphocytic Lymphoma with Bendamustine and Rituximab

[Guest guest]

BlankTreatment of Synchronous Mantle Cell Lymphoma and Small Lymphocytic

Lymphoma with Bendamustine and Rituximab.

TV Kourelis, BS Kahl, P Benn, JA Delach, and SF Bilgrami

Acta Haematol, March 23, 2011; 126(1): 40-43.

Department of Medicine, Saint Francis Hospital and Medical Center, Hartford,

Conn., USA.

Herein, we describe a case of a female patient in whom B cell chronic

lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) were diagnosed

simultaneously. She presented with anemia, thrombocytopenia and splenomegaly.

Flow cytometry demonstrated two immunophenotypically distinct CD5-positive

monoclonal B cell populations. Peripheral blood fluorescence in situ

hybridization (FISH) was positive for IGH/CCND1, consistent with t(11;14)

translocation. She received 6 cycles of bendamustine 70 mg/m(2)/day for 2 days

and rituximab on the first day every 4 weeks along with granulocyte-colony

stimulating factor. She had an excellent response, and repeat computed

tomography after her third cycle of chemotherapy revealed no organomegaly or

lymphadenopathy. Her peripheral blood lymphocytosis also resolved. Bone marrow

examination revealed no detectable flow-cytometric evidence of MCL or CLL.

Repeat cytogenetic and FISH analysis were also normal. The patient remains in

complete remission 20 months after her initial diagnosis and is receiving

maintenance rituximab 375 mg/m(2) weekly for 4 weeks every 6 months for 2 years.

PMID: 21430370